News
SXTP
2.960
-4.52%
-0.140
GEOFF DOW, PHD, INFECTIOUS DISEASE PRODUCT DEVELOPMENT EXPERT, TO DISCUSS BABESIOSIS AT HEALING LYME SUMMIT, APRIL 15-21
Reuters · 3d ago
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 4d ago
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 4d ago
BUZZ-U.S. STOCKS ON THE MOVE-Walgreens, Harley-Davidson, Hewlett Packard Enterprise
Reuters · 5d ago
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 5d ago
Dow Jumps Over 1,100 Points; US Small Business Sentiment Falls In March
Benzinga · 5d ago
60 Degrees Pharmaceuticals signs Patient License Agreement with Yale
TipRanks · 5d ago
SIXTY DEGREES PHARMACEUTICALS ANNOUNCES PATENT LICENSE AGREEMENT TO ADVANCE DEVELOPMENT OF TAFENOQUINE FOR BABESIOSIS TREATMENT AND PREVENTION WITH YALE SCHOOL OF MEDICINE AND YALE SCHOOL OF PUBLIC HEALTH
Reuters · 5d ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 5d ago
Weekly Report: what happened at SXTP last week (0331-0404)?
Weekly Report · 6d ago
Weekly Report: what happened at SXTP last week (0324-0328)?
Weekly Report · 03/31 12:22
60 Degrees Pharmaceuticals GAAP EPS of -$18.55
Seeking Alpha · 03/28 16:57
HC Wainwright & Co. Reiterates Neutral on 60 Degreesto Neutral
Benzinga · 03/28 11:09
Press Release: 60 Degrees Pharmaceuticals Announces 2024 Annual Results
Dow Jones · 03/28 10:59
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Lucid Diagnostics (LUCD), LENSAR (LNSR) and 60 Degrees Pharmaceuticals, Inc. (SXTP)
TipRanks · 03/28 10:30
60 Degrees Pharmaceuticals Announces 2024 Annual Results
Barchart · 03/28 05:59
Based on the provided financial report articles, the title of the article is: "60 DEGREES PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) FORM 10-K ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024
Press release · 03/27 20:51
Weekly Report: what happened at SXTP last week (0317-0321)?
Weekly Report · 03/24 12:06
Weekly Report: what happened at SXTP last week (0310-0314)?
Weekly Report · 03/17 12:21
Weekly Report: what happened at SXTP last week (0303-0307)?
Weekly Report · 03/10 12:22
More
Webull provides a variety of real-time SXTP stock news. You can receive the latest news about 60 degrees pharmaceuticals, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About SXTP
More
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is used for malaria prevention in individuals 18 years and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.